Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Enoblituzumab vs Standard of Care in High-Risk Localized Prostate Cancer
NCT06014255Phase 2Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 2024
- Primary completion
- Mar 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of enoblituzumab in prostate cancer (PCa), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Feb 2024; status: active, not recruiting.
02
Drugs
enoblituzumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06014255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06014255.